Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ESSENTIAL Protocol No. My-021 and Protocol No. My-026, Each Titled: A Phase III, Randomized, Double-Blind, Multicenter, Parallel Group, Placebo-Controlled Study of Oral Enoximone vs. Placebo in Advanced Chronic Heart Failure Subjects

NCT00051285 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT00051285
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00051285 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ESSENTIAL Protocol No. My-021 and Protocol No. My-026, Each Titled: A Phase III, Randomized, Double-Blind, Multicenter, Parallel Group, Placebo-Controlled Study of Oral Enoximone vs. Placebo in Advanced Chronic Heart Failure Subjects
Lead sponsor
Gilead Sciences
Phase
Phase 3
Overall status
Terminated
Start date
February 28, 2002
Completion date
June 30, 2005
Enrollment
1,800
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure, congestive